Biosergen AB (OSTO:BIOSGN) Return-on-Tangible-Asset: -219.85% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:BIOSGN Biosergen AB OSTO:BIOSGN
24 GF Score
Price kr0.55
View Full Analysis

What is Biosergen AB Return-on-Tangible-Asset?

Biosergen AB OSTO:BIOSGN -54.58% 24 Return-on-Tangible-Asset is -219.85% as of Dec. 2025. GuruFocus rates OSTO:BIOSGN with a GF Score™ of 24/100. Among 1,410 Biotechnology companies, Biosergen AB ranks worse than 87.02% on this metric.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Biosergen AB's annualized Net Income for the quarter that ended in Dec. 2025 was kr-49.85 Mil. Biosergen AB's average total tangible assets for the quarter that ended in Dec. 2025 was kr28.88 Mil. Therefore, Biosergen AB's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -219.85%.

The historical rank and industry rank for Biosergen AB's Return-on-Tangible-Asset or its related term are showing as below:

OSTO:BIOSGN' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -200.2   Med: -119.77   Max: -63.75
Current: -142.59

During the past 6 years, Biosergen AB's highest Return-on-Tangible-Asset was -63.75%. The lowest was -200.20%. And the median was -119.77%.

OSTO:BIOSGN's Return-on-Tangible-Asset is ranked worse than
87.02% of 1410 companies
in the Biotechnology industry
Industry Median: -35.38 vs OSTO:BIOSGN: -142.59

Biosergen AB  (OSTO:BIOSGN) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Biosergen AB Return-on-Tangible-Asset Related Terms


Biosergen AB Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Biosergen AB's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosergen AB Return-on-Tangible-Asset Chart

Biosergen AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Asset
Get a 7-Day Free Trial -200.20 -107.62 -131.92 -63.75 -104.36

Biosergen AB Quarterly Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only -276.99 -102.58 -26.52 -103.60 -219.85

OSTO:BIOSGN vs VRTX, REGN, MRNA: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Biosergen AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosergen AB Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biosergen AB's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Biosergen AB's Return-on-Tangible-Asset falls into.


OSTO:BIOSGN
24GF Score
Biosergen AB OSTO:BIOSGN
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosergen AB Return-on-Tangible-Asset Calculation

Biosergen AB's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-38.013/( (53.022+19.828)/ 2 )
=-38.013/36.425
=-104.36 %

Biosergen AB's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-49.852/( (37.926+19.828)/ 2 )
=-49.852/28.877
=-172.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2025) net income data.

What does a Return-on-Tangible-Asset of -219.85% mean?
Biosergen AB (OSTO:BIOSGN) has a Return-on-Tangible-Asset of -219.85% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Biosergen AB and its competitors. According to the industry distribution chart, Biosergen AB ranks #1227 out of 1410 companies in the Biotechnology industry, placing it in the top 87%.
Is Biosergen AB's Return-on-Tangible-Asset too high?
Biosergen AB's current Return-on-Tangible-Asset is -219.85%. Based on the distribution chart, Biosergen AB ranks #1227 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Biosergen AB has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Biosergen AB's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biosergen AB ranks #1227 out of 1410 companies for Return-on-Tangible-Asset. This places Biosergen AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Biosergen AB and its competitors. Biosergen AB's current Return-on-Tangible-Asset is -219.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosergen AB stock overvalued right now?
Biosergen AB (OSTO:BIOSGN) has a current Return-on-Tangible-Asset of -219.85%. The current Return-on-Tangible-Asset is -219.85%. Biosergen AB's overall GF Score™ is 24/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Biosergen AB (OSTO:BIOSGN), the current Return-on-Tangible-Asset is -219.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biosergen AB Business Description

Address Fogdevreten 2, Solna, SWE, 17165
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen' s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.
24GF Score

Get the complete analysis for OSTO:BIOSGN

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.55
Price